Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Sold by Prudential Financial Inc.

Prudential Financial Inc. trimmed its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 43.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 145,510 shares of the company's stock after selling 110,400 shares during the quarter. Prudential Financial Inc. owned 0.14% of Dyne Therapeutics worth $3,428,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Quantbot Technologies LP purchased a new position in shares of Dyne Therapeutics during the 3rd quarter worth about $34,000. Point72 DIFC Ltd purchased a new position in shares of Dyne Therapeutics during the third quarter valued at approximately $36,000. KBC Group NV grew its stake in shares of Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company's stock valued at $74,000 after buying an additional 978 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Dyne Therapeutics during the fourth quarter valued at approximately $257,000. Finally, Magnetar Financial LLC purchased a new stake in shares of Dyne Therapeutics in the fourth quarter worth approximately $263,000. Institutional investors own 96.68% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on DYN. Robert W. Baird began coverage on Dyne Therapeutics in a research report on Friday, December 13th. They issued an "outperform" rating and a $46.00 price objective on the stock. Raymond James upgraded shares of Dyne Therapeutics to a "strong-buy" rating in a report on Thursday, December 12th. Baird R W upgraded shares of Dyne Therapeutics to a "strong-buy" rating in a report on Thursday, December 12th. Scotiabank began coverage on shares of Dyne Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 target price on the stock. Finally, Chardan Capital reaffirmed a "buy" rating and set a $50.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Dyne Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $47.46.

Remove Ads

Dyne Therapeutics Price Performance

Dyne Therapeutics stock traded down $1.14 during trading hours on Friday, reaching $8.28. The stock had a trading volume of 2,602,714 shares, compared to its average volume of 1,424,942. The company has a market cap of $936.64 million, a price-to-earnings ratio of -2.33 and a beta of 1.11. The business's 50 day moving average price is $12.92 and its 200-day moving average price is $22.87. Dyne Therapeutics, Inc. has a 52 week low of $8.15 and a 52 week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, beating analysts' consensus estimates of ($0.92) by $0.04. On average, sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the sale, the insider now owns 199,087 shares of the company's stock, valued at approximately $2,777,263.65. The trade was a 1.29 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 6,237 shares of company stock valued at $77,760 in the last quarter. 20.77% of the stock is currently owned by corporate insiders.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.